Safety and Efficacy Evaluation of HS135 in Adults With Pulmonary Arterial Hypertension: An Early Phase Clinical Trial

The primary objective of this early phase study is to evaluate the **safety** and **efficacy** of HS135 in adult patients diagnosed with **pulmonary arterial hypertension** (PAH). Pulmonary arterial hypertension is a progressive condition characterized by high blood pressure in the arteries of the lungs, leading to right heart failure and significant morbidity. Assessing the safety profile and therapeutic potential of HS135 is clinically relevant as it may offer a new treatment avenue for managing this debilitating disease.

The clinical trial involves a total of **20 participants** diagnosed with **pulmonary arterial hypertension**. The study population includes both male and female subjects, with an age range spanning from 18 to 65 years. Participants were selected to ensure a representative sample of the general population affected by this condition, including those considered part of a vulnerable population. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The sponsor has not provided detailed information regarding the main objective of the trial or specific inclusion criteria.

The clinical trial is designed to evaluate the **safety** and **efficacy** of HS135 in adult patients diagnosed with **pulmonary arterial hypertension**. This study is categorized as a Phase 3 trial and is structured as a randomized, double-blind, controlled trial. The estimated recruitment start date is June 3, 2024, with an anticipated completion date of July 15, 2026. The trial will involve a series of study visits, beginning with an inclusion visit, which serves as a screening to determine participant eligibility based on predefined criteria. Following successful inclusion, participants will undergo a series of follow-up visits at regular intervals to monitor their response to the treatment and assess any adverse effects. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the intervention.

Participants are expected to be involved in the study for its entire duration unless specific conditions necessitate early termination. Such conditions may include the occurrence of significant adverse events, withdrawal of consent, or non-compliance with study protocols. The trial's methodology ensures that all participants and investigators remain blinded to the treatment assignments to maintain the integrity of the data collected. The study's design and procedures are meticulously planned to ensure the collection of reliable and valid data, contributing to the understanding of HS135's potential benefits and risks in treating pulmonary arterial hypertension.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a paediatric formulation or if it is classified as an orphan drug. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the study may include the use of non-experimental treatments such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these non-experimental treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these treatments is also not available in the provided data.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on June 3, 2024, with an estimated completion date of July 15, 2026. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters, adhering to the rigorous standards expected in a Phase 3 trial. The trial's design will ensure that data collection and analysis are conducted systematically to provide reliable and valid results regarding the efficacy of the intervention under investigation.